Holen Sie sich die Stockscreener-App
9.80
4.39%
-0.45
Handel nachbörslich:
9.65
-0.15
-1.53%
Schlusskurs vom Vortag:
$10.25
Offen:
$10.25
24-Stunden-Volumen:
910.94K
Relative Volume:
1.06
Marktkapitalisierung:
$853.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-106.81M
KGV:
-2.9592
EPS:
-3.3117
Netto-Cashflow:
$-8.40M
1W Leistung:
-1.01%
1M Leistung:
-10.50%
6M Leistung:
+9.13%
1J Leistung:
-33.38%
1-Tages-Spanne:
$9.54
$10.31
1-Wochen-Bereich:
$9.13
$10.31
52-Wochen-Spanne:
$5.1501
$16.73
Immunome Inc Stock (IMNM) Company Profile
Firmenname
Immunome Inc
Sektor
Branche
Telefon
610-321-3700
Adresse
18702 N. CREEK PARKWAY, BOTHELL
Vergleichen Sie IMNM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
9.80 | 807.78M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | Lake Street | Buy |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-30 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-01-29 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-19 | Eingeleitet | Wedbush | Outperform |
| 2021-10-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Immunome Inc Aktie (IMNM) Neueste Nachrichten
How does Immunome Inc. perform in inflationary periodsJuly 2025 Patterns & Fast Exit and Entry Trade Guides - khodrobank.com
Published on: 2025-09-03 09:01:24 - Newser
Iovance Biotherapeutics shares rise 1.32% premarket after Immunome's presentation at H.C. Wainwright conference. - AInvest
Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
Will Immunome Inc. continue its uptrendMarket Risk Report & AI Enhanced Execution Alerts - Newser
Visual trend scoring systems applied to Immunome Inc.2025 Volume Leaders & Fast Gain Swing Trade Alerts - Newser
Why Immunome Inc. stock attracts strong analyst attention2025 Performance Recap & Step-by-Step Swing Trade Plans - Newser
Using data filters to optimize entry into Immunome Inc.Market Movers & High Accuracy Buy Signal Tips - Newser
Will Immunome Inc. price bounce be sustainablePortfolio Return Report & High Accuracy Swing Entry Alerts - Newser
Regression analysis insights on Immunome Inc. performanceShare Buyback & Verified Trade Idea Suggestions - Newser
Analyzing net buyer seller activity in Immunome Inc.Market Trend Review & Verified Technical Signals - Newser
Price momentum metrics for Immunome Inc. explainedMarket Risk Summary & Safe Swing Trade Setup Alerts - Newser
What is the long term forecast for Immunome Inc. stockMarket Performance Recap & High Conviction Trade Alerts - khodrobank.com
Using data models to predict Immunome Inc. stock movementTreasury Yields & AI Powered Market Entry Ideas - Newser
Is Immunome Inc. trending in predictive chart modelsInsider Selling & Free Daily Entry Point Trade Alerts - Newser
Can Traders Expect Breakout From Immunome Inc. This Week2025 Geopolitical Influence & AI Enhanced Market Trend Forecasts - beatles.ru
Will Immunome Inc. bounce back from current supportTrade Volume Report & Real-Time Volume Surge Alerts - Newser
Is Immunome Inc. building a consolidation baseInsider Buying & Daily Entry Point Trade Alerts - Newser
Published on: 2025-09-01 15:41:00 - Newser
Analyzing recovery setups for Immunome Inc. investorsJobs Report & Daily Momentum Trading Reports - Newser
Will earnings trigger a reversal in Immunome Inc.Inflation Watch & High Return Trade Guides - Newser
Using Bollinger Bands to evaluate Immunome Inc.Chart Signals & Safe Entry Point Alerts - Newser
Trend Dashboard Flags Immunome Inc. As Potential Swing Trade getLinesFromResByArray error: size == 0 - sisaissue.com
Is Immunome Inc. a candidate for recovery playPortfolio Risk Report & Weekly Chart Analysis and Guides - Newser
Immunome Inc. Uptrend in Early Stages Indicators Say YesJuly 2025 Analyst Calls & Risk Managed Trade Strategies - beatles.ru
What Fibonacci levels say about Immunome Inc. rebound2025 Retail Activity & Safe Entry Point Alerts - Newser
Risk vs reward if holding onto Immunome Inc.Treasury Yields & Advanced Swing Trade Entry Alerts - Newser
Immunome Inc. Price Holds Above Key Fib Level getLinesFromResByArray error: size == 0 - 클래시안
Immunome Inc.’s volatility index tracking explainedMarket Activity Report & Target Return Focused Stock Picks - Newser
How to forecast Immunome Inc. trends using time seriesJuly 2025 Closing Moves & Technical Pattern Recognition Alerts - Newser
Short interest data insights for Immunome Inc.Trade Volume Report & Reliable Volume Spike Trade Alerts - Newser
Will Immunome Inc. stock recover after recent dropWeekly Risk Summary & Daily Price Action Insights - Newser
Finanzdaten der Immunome Inc-Aktie (IMNM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunome Inc-Aktie (IMNM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
| Tsai Philip | Chief Technology Officer |
Mar 24 '25 |
Buy |
8.42 |
12,300 |
103,566 |
33,300 |
| SIEGALL CLAY B | President and CEO |
Jan 31 '25 |
Buy |
7.75 |
150,000 |
1,162,500 |
669,636 |
| SIEGALL CLAY B | President and CEO |
Nov 21 '24 |
Buy |
9.54 |
66,057 |
630,263 |
485,693 |
| SIEGALL CLAY B | President and CEO |
Nov 22 '24 |
Buy |
9.78 |
33,943 |
331,918 |
519,636 |
| Lechleider Robert | Chief Medical Officer |
Nov 21 '24 |
Buy |
9.48 |
15,805 |
149,800 |
15,805 |
| Tsai Philip | Chief Technology Officer |
Nov 21 '24 |
Buy |
9.43 |
21,000 |
198,030 |
21,000 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):